Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia - Test2 - elhamkhani - TriplyDB

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia

http://www.wikidata.org/entity/Q30459624

about

Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs.Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures survey A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100 A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.Intracranial self-stimulation to evaluate abuse potential of drugs.The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.Development of allosteric modulators of GPCRs for treatment of CNS disorders The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis.Inhibition of cholinergic pathways in Drosophila melanogaster by α-conotoxins.Axon targeting of the alpha 7 nicotinic receptor in developing hippocampal neurons by Gprin1 regulates growth.Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.Investigational dopamine antagonists for the treatment of schizophrenia.Neural circuitry and immunity.State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects Galantamine effect on tularemia pathogenesis in a BALB/c mouse model.Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice Cholinergic connectivity: it's implications for psychiatric disorders.Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker Cholinergic neurons excite cortically projecting basal forebrain GABAergic neurons.Chromosome conformation elucidates regulatory relationships in developing human brain.Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.Use of allosteric targets in the discovery of safer drugs.Nicotinic modulation of intrinsic brain networks in schizophrenia.Leading compounds for the validation of animal models of psychopathology.Muscarinic acetylcholine receptors: novel opportunities for drug development.Emerging drugs for schizophrenia: an update.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.Cognitive impairment in schizophrenia: the great unmet need.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

P2860

Q27693888-8DCF9A3C-A561-4AE7-A833-5281DF0DE5D2 Q28072198-2528916A-2883-431C-95A7-364595B3C267 Q28487183-07B96671-59C4-40D2-A5E2-6C6262D036B0 Q28487975-8B8A2676-954C-43BB-A10D-EE02971D41E1 Q30381001-A344073F-AA6B-4047-8147-53B4B4453E48 Q30406145-0CFB23B9-2968-42FA-9F1C-44A520CA8620 Q30410518-00C5DBA0-8AF1-49CD-85CB-2E467FCBBB06 Q33624417-034E3298-412A-4818-9077-B577B06F36D2 Q33845750-C95F6819-F6E7-4421-9A8A-D51C45C349C3 Q33920257-0708F45C-A97E-4932-80BE-073387F91EDC Q34373958-760B6A2A-C77C-4569-827F-CBF6E1CF466D Q34455707-81DD71FC-C265-49AC-9C65-EEE395CC21F4 Q34580443-4D3413AF-BD24-4B08-84D6-978D14C07265 Q34613107-D59EEADF-8B0B-4A10-84CC-531C6D23D956 Q35576500-95378DB5-7B46-423C-A478-81F0902753E6 Q35834299-4E3941CF-833B-440D-9222-BAFB5788730C Q36174107-31245F6C-D103-46DC-BF88-0903919D9707 Q36219281-32AA1A4B-F5A4-49C0-AD8D-F828EEF3F7DA Q36356306-168EFFDA-0615-4F4F-893C-F775111F2694 Q36551920-C7B919BF-1857-4B65-B59A-8CBABF7E0BBC Q36732752-4C6D53AB-339A-4BDA-98C8-75D79C9C444B Q36777164-3E0793F8-9D8F-4386-9EF9-31A3771D6C1B Q36794968-2251C3F6-DA34-4153-AD98-8CE61253C66F Q36812599-65D103B9-7B65-4484-975E-9C6C9B2C1A7F Q37067455-5663B6E3-F331-4E74-9C62-B19F62D96BD0 Q37258840-127E5630-F01D-40B9-A73B-EAC033833F24 Q37597240-7BB49636-3A1A-4DC3-B551-7F2595D3ED8A Q37712138-ABB4C8B2-2D71-4D31-86D9-F36D21429E92 Q38070176-D1A66E26-C789-4D63-9C17-B58A11357AF1 Q38109800-D6366536-D145-47F6-8D0D-DC2100ECD2CC Q38116676-EBE0C46A-6777-43B4-A4C5-9C9DB9133F85 Q38128733-6451B2E1-2247-480F-813D-6C59FD81F27B Q38218059-4D357707-D851-4845-AAD5-C97BECE95E6C Q38252404-B1AD23F3-B762-4F7B-A924-F66F5A5803E8 Q38268878-208C6323-5B50-45A7-8C20-189AFFDC32AC Q38436762-13E88964-3173-4AEA-A2F3-53ABC458F1D6 Q38437959-092A972B-C551-4B0B-8FB3-0A1691AE1547 Q38560778-82AD096A-E413-421E-A322-69821D7D700A Q38673548-78B422FE-7C10-4A9F-8D0D-F001CDDE6393 Q38699013-8BD33E8A-9E85-4820-9C1C-B934FFF20423

P2860

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia

http://www.wikidata.org/entity/Q30459624

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@ast

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@en

type

label

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@ast

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@en

prefLabel

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@ast

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@en

P1433

Q30459624-BDB66DDC-78D2-4058-884B-B7D8073834E7

P1476

Q30459624-3D329816-00DA-461E-9317-F2ABC8FE7F74

P2093

Q30459624-4408B543-450C-4AE8-B05A-D1E2C14BB563

Q30459624-C7B28D97-0074-4548-AF5A-CA7AA8DEC14F

Q30459624-F7716C9C-0B05-4666-A4E2-3A225F81A2A5

P2860

Q30459624-00A33C4C-0FB5-4FDA-AC10-89230A2C6323

Q30459624-00B03F0F-3CC7-419B-8A47-4CDC041BDE38

Q30459624-00C1D212-1149-4769-B5DD-25C577063651

Q30459624-00F4926E-1704-4E3A-BD5A-08C5F0B56CB9

Q30459624-01742EAE-65A1-4F9D-83F5-B0AFC71499BB

Q30459624-01A0E74E-967E-4762-B3EE-207796444992

Q30459624-01BA3AB7-ECF8-43C7-A216-48FF3733CA33

Q30459624-0232C295-AD8A-406E-A932-AF47A8F32E2C

Q30459624-0351EA9F-F98C-4808-909C-06B245D84DBC

Q30459624-038179A0-B08F-47A3-A04E-0702EDFDB30B

P2888

Q30459624-1C06F614-3CA1-4687-97F2-47B5F2E4A9D1

P304

Q30459624-0B2EFB80-C88A-49B7-B1D3-6E023195ED1E

P31

Q30459624-8F3F4C1F-3884-4D68-AB2C-AF643BBE0825

P356

Q30459624-DFDBDB07-3CC9-4455-A64A-AB61BDDA2468

P407

Q30459624-FBF5CD06-D1F0-49EC-B355-154BA9ADF9E3

P433

Q30459624-49E17EC3-6B40-4FA8-9F1A-6295B65402F5

P478

Q30459624-A79C0D18-4FCA-42D1-A7BC-A7BFACD0F302

P577

Q30459624-8F654D75-69A2-4658-AF5C-F1A5229E9E6E

P5875

Q30459624-4542FCD2-63A0-43AE-87A8-C5AC43FDA6D1

P6179

Q30459624-5089EFEF-31D7-4F60-A3A5-DE0EB6AA36D9

P698

Q30459624-FDDD03EA-6394-4569-96D1-7534CAF44C23

P921

Q30459624-A7A66A19-BF2F-453C-8EFA-3AAC9B47E502

Q30459624-B488DE38-045D-4512-B779-EB38C2C3C588

P932

Q30459624-338CCB8C-3C8D-4034-B846-9DEA43D662A6

P356

P1433

Neuropsychopharmacology

P1476

Muscarinic and nicotinic acety ...... the treatment of schizophrenia

@en

P2093

Carrie K Jones

http://www.w3.org/2001/XMLSchema#string

Michael Bubser

http://www.w3.org/2001/XMLSchema#string

Nellie Byun

http://www.w3.org/2001/XMLSchema#string

P2860

The dopamine hypothesis of schizophrenia: version III--the final common pathway

Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes

Differential coupling of m2 and m4 muscarinic receptors to inhibition of adenylyl cyclase by Gi alpha and G(o)alpha subunits

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice.

Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1

A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors

Mammalian nicotinic acetylcholine receptors: from structure to function

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

P2888

P304

16-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2011.199

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51679079

http://www.w3.org/2001/XMLSchema#string

P6179

1016959373

http://www.w3.org/2001/XMLSchema#string

P698

21956443

http://www.w3.org/2001/XMLSchema#string

P921

P932

3238081

http://www.w3.org/2001/XMLSchema#string